Dr. Arnold Silva, MD, PHD

Payments from drug and device companies

In 2025, 12 companies reported 174 payments worth $103,928 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Idaho →

Industry-funded research

Named as a principal investigator on 14 industry-funded studies in 2025, from 9 companies. The companies reported $347,489 in research payments for these studies, mostly to the institutions running them.

• A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Povetacicept in Adults With Immunoglobulin A Nephropathy (RAINIER)
  Vertex Pharmaceuticals Incorporated
• Phase 2 Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
  Alexion Pharmaceuticals, Inc.
• A Phase 2b/3 Adaptive, Randomized, Active-controlled Study Evaluating the Efficacy, Safety, and Tolerability of Povetacicept Versus Calcineurin Inhibitor in the Treatment of Primary Membranous Nephropathy
  Vertex Pharmaceuticals Incorporated
• PROTECT Study in IgA Nephropathy
  Travere Therapeutics, Inc.
• A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
  Takeda Pharmaceuticals U.S.A., Inc. · Recruiting · NCT06963827
• A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
  AbbVie Inc.
• DUPLEX study in FSGS
  Travere Therapeutics, Inc.
• A Randomized, Double Blind, Placebo Controlled, Multicenter, Parallel Group, Dose Ranging Study to Evaluate CIN 107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease
  AstraZeneca Pharmaceuticals LP
• TAK-079-1006A study of mezagitamab in adults with primary immunoglobulin a nephropathy receiving stable background therapy
  Takeda Pharmaceuticals U.S.A., Inc.
• SPARTACUS
  Travere Therapeutics, Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Nephrology (Kidney) clinicians in Meridian

• Robert L. Davidson, M.D.
• Mary O. Dittrich, MD
• Aaron Fearday, M.D.
• Amanda K. Hall, D.O.
• Jerry Meng, MD
• Kevin Mitchell, MBBS
• Amit Sharma, MD, FACP, FASN
• Liang Wu, MD